AB284130

Anti-N6-methyladenosine (m6A) antibody [EPR23561-164]

20ul selling size
RabMAb
Recombinant
What is this?

Be the first to review this product! Submit a review

(48 Publications)

Anti-N6-methyladenosine (m6A) antibody [EPR23561-164] (ab284130) is a rabbit monoclonal antibody detecting N6-methyladenosine (m6A) in Dot Blot.

- Biophysical QC for unrivalled batch-batch consistency
- Over 20 publications

View Alternative Names

N6-methyladenosine, m6A

3 Images

Supplier Data

Dot Blot - Anti-N6-methyladenosine (m6A) antibody [EPR23561-164] (AB284130)

Dot blot analysis of N6-methyladenosine (m6A) using ab284130 at 1/5000 (0.0001μg/mL) followed by a Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ab97051) at 1/20,000 dilution.

Lane 1 : HeLa total RNA

Lane 2 : HeLa mRNA

Exposure time : 20 seconds

Blocking and diluting buffer and concentration : 5% NFDM/TBST

FRET - Anti-N6-methyladenosine (m6A) antibody [EPR23561-164] (AB284130)

FRET

Supplier Data

FRET - Anti-N6-methyladenosine (m6A) antibody [EPR23561-164] (AB284130)

HTRF was performed on 25 nm of each biotinylated oligos and using ab284130 at a concentration range of 0.001-4.000 ug/ml. Species-specific Terbium cryptate- labelled anti-rabbit IgG antibody and D2-labeled Streptavidin were used.

Supplier Data

Dot Blot - Anti-N6-methyladenosine (m6A) antibody [EPR23561-164] (AB284130)

Dot blot analysis of N6-methyladenosine (m6A) using ab284130 at 1/5000 (0.0001μg/mL) followed by a Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ab97051) at 1/20,000 dilution.

Lane 1 : m6, 6A-oligo

Lane 2 : A-oligo

Lane 3 : Am-oligo

Lane 4 : m6A-oligo

Lane 5 : m6Am-oligo

Exposure time : 6 seconds

Blocking and diluting buffer and concentration : 5% NFDM/TBST

Carrier free

Anti-N6-methyladenosine (m6A) antibody [EPR23561-164] - BSA and Azide free

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR23561-164

Isotype

IgG

Carrier free

Applications

Dot, FRET

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

style

left-column

style

left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "Dot" : {"fullname" : "Dot Blot", "shortname":"Dot"}, "FRET" : {"fullname" : "FRET", "shortname":"FRET"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Modified Nucleic Acid": { "Dot-species-checked": "testedAndGuaranteed", "Dot-species-dilution-info": "1/5000", "Dot-species-notes": "<p></p>", "FRET-species-checked": "testedAndGuaranteed", "FRET-species-dilution-info": "0.001-4 µg/mL", "FRET-species-notes": "<p></p>" } } }

style

left-column

Product details

What is this antibody validated in?
Anti-N6-methyladenosine (m6A) antibody [EPR23561-164] (ab284130) is a rabbit recombinant monoclonal antibody and is validated for use in Dot Blot.

Trusted by the scientific community
Anti-N6-methyladenosine (m6A) [EPR23561-164] (ab284130) was first used in a scientific publication in 2021 and has been cited over 20 times in peer-reviewed journals.

Other related products
We have a range of other formats of antibody clone [EPR23561-164] also available for your convenience: ab284130, Carrier free - ab284136

Patented technology
Our RabMAb^® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb^® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production

For more information, read more on recombinant antibodies.

Trial sizes available!
Test your antibody or perform pre-screening before committing to a larger quantity. Sold in 20µl. Discover our selection of trial-size antibodies.

style

left-column

Properties and storage information

Form

Liquid

Purification technique

Affinity purification Protein A

Storage buffer

pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA

Shipped at conditions

Conditional Ambient

Appropriate short-term storage duration

1-2 weeks

Appropriate short-term storage conditions

+4°C

Appropriate long-term storage conditions

-20°C

Aliquoting information

Upon delivery aliquot

Storage information

Avoid freeze / thaw cycle

style

left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

N6-methyladenosine (m6A) is a chemical modification present in RNA molecules specifically marking the adenosine base with a methyl group at the nitrogen-6 position. This modification weighing approximately 14 Da occurs in diverse eukaryotic species and influences RNA metabolism. m6A methylation can be detected using techniques like m6A dots blot or m6A ELISA. The modification is abundant in tissues like the brain and testis reflecting its critical role in varying cell types. Also m6A is known as a dynamic and reversible mark with its levels continuously adjusted by enzymes called writers (methyltransferases) erasers (demethylases) and readers (RNA-binding proteins).

Biological function summary

M6A methylation affects mRNA processing stability translation and decay. It integrates into large multi-protein complexes where it influences gene expression outcomes by affecting the RNA's interaction with the cellular machinery. This methylation modification acts as a regulatory signal that influences essential processes such as cell differentiation and circadian rhythms. Elucidating the biological functions of m6A involves studying how it affects RNA fate and its downstream gene regulatory networks.

Pathways

M6A modification is central to the mRNA metabolic pathway and the PI3K-Akt signaling pathway. It interacts with various proteins such as METTL3 an m6A methyltransferase which is vital for mediating m6A modification. It also interacts with YTH domain-containing proteins that recognize m6A marks influencing transcript dynamics and gene expression. The interplay of m6A with proteins in these pathways underlines its role in fine-tuning cellular processes and responses.

M6A modification has a significant impact on cancer and neurological disorders. In cancers alterations in m6A methylation patterns can promote oncogenic transformation and metastasis. m6A-related proteins such as FTO an m6A demethylase have shown connections to these pathways affecting cancer progression. In neurological disorders m6A impacts aspects of neural development and function and abnormalities in its regulation may contribute to diseases like Alzheimer's. Understanding the roles of m6A in diverse diseases can pave the way for novel therapeutic approaches.

style

left-column

style

left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

Target data

See full target information N6-methyladenosine (m6A)

style

left-column

Publications (48)

Recent publications for all applications. Explore the full list and refine your search

iScience 28:113520 PubMed41069850

2025

ALKBH5-IGF2BP2 axis mediates prostate cancer progression and docetaxel resistance via m6A-stabilized CLSPN RNA.

Applications

Unspecified application

Species

Unspecified reactive species

Yutong Chen,Yang Li,Zongzhu Liang,Zhao Yang,Haotian Ren,Wanqing Wei,Yuanjie Niu,Zhiqun Shang

Frontiers in oncology 15:1652621 PubMed40978048

2025

Dynamic alterations in mA RNA methylation profiles during involution of infantile hemangiomas.

Applications

Unspecified application

Species

Unspecified reactive species

Pinru Wu,Qingqing Cen,Ying Shang,Junyan Liang,Gang Ma

Diabetic medicine : a journal of the British Diabetic Association 42:e70087 PubMed40509919

2025

Astragaloside IV alleviates diabetic foot ulcers by promoting the METTL3-mediated m6A modification of SIRT1.

Applications

Unspecified application

Species

Unspecified reactive species

Yu Liu,Hao Zheng,Jiayuan Zhang

BMC pharmacology & toxicology 26:79 PubMed40211323

2025

Saikosaponin D inhibits the inflammatory response of secretory otitis media through FTO-mediated N-methyladenosine modification of TLR4 mRNA.

Applications

Unspecified application

Species

Unspecified reactive species

Minjing Yin,Xiuli Han

Acta biochimica et biophysica Sinica 57:1106-1114 PubMed40109092

2025

METTL3-mediated m A modification of pri-miRNA-31 promotes hypertrophic scar progression.

Applications

Unspecified application

Species

Unspecified reactive species

Qirui Wang,Jialin Hou,Siyi Zeng,Xue Wang,Yimin Liang,Renpeng Zhou

Communications biology 8:457 PubMed40102597

2025

Peli1, regulated by mA modification, suppresses NLRP3 inflammasome activation in atherosclerosis by inhibiting YB-1.

Applications

Unspecified application

Species

Unspecified reactive species

Qiang Liu,Lu Yan,Tao Wu,Qinghua Wu,Ben Ke,Wen Shen

Cancer communications (London, England) 45:608-631 PubMed39960839

2025

Helicobacter pylori CagA elevates FTO to induce gastric cancer progression via a "hit-and-run" paradigm.

Applications

Unspecified application

Species

Unspecified reactive species

Bing He,Yiyang Hu,Yuyun Wu,Chao Wang,Limin Gao,Chunli Gong,Zhibin Li,Nannan Gao,Huan Yang,Yufeng Xiao,Shiming Yang

Cell biology and toxicology 41:38 PubMed39875576

2025

Esketamine alleviates depressive-like behavior in neuropathic pain mice through the METTL3-GluA1 pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Xiaoming Ji,Zhimin Huang,Chenming Zhou,Yu Wang,Dongliang Geng,Guoliang Zhang,Yunxiao Kang,Rui Cui,Jinyang Wang,Tianyun Zhang

Gut microbes 17:2438471 PubMed39852343

2025

Novel role of FTO in regulation of gut-brain communication via -produced hydrogen sulfide under arsenic exposure.

Applications

Unspecified application

Species

Unspecified reactive species

Ruonan Chen,Xiaoqin Chai,Yunxiao Zhang,Tianxiu Zhou,Yinyin Xia,Xuejun Jiang,Bo Lv,Jun Zhang,Lixiao Zhou,Xin Tian,Ruonan Wang,Lejiao Mao,Feng Zhao,Hongyang Zhang,Jun Hu,Jingfu Qiu,Zhen Zou,Chengzhi Chen

Cell biology international 49:288-302 PubMed39687949

2024

Wilms' tumor 1-associated protein aggravates ischemic stroke by promoting M1 polarization of microglia by enhancing PTGS2 mRNA stability in an m6A-dependent manner.

Applications

Unspecified application

Species

Unspecified reactive species

Haijing Sui,Chang Liu,Zhenyu Sun,Hongjie Xi

View all publications

style

left-column

style

left-column

style

right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.

For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com

Anti-N6-methyladenosine (m6A) antibody [EPR23561-164]

Dot Blot - Anti-N6-methyladenosine (m6A) antibody [EPR23561-164] (AB284130)

FRET - Anti-N6-methyladenosine (m6A) antibody [EPR23561-164] (AB284130)

Dot Blot - Anti-N6-methyladenosine (m6A) antibody [EPR23561-164] (AB284130)

Related conjugates and formulations (1)

Key facts

Host species

Clonality

Clone number

Isotype

Carrier free

Applications

Immunogen

Complementary Products

Assay Kits

Primary Antibodies

Primary Antibodies

Secondary Antibodies

Primary Antibodies

Reactivity data

Product details

Properties and storage information

Form

Purification technique

Storage buffer

Shipped at conditions

Appropriate short-term storage duration

Appropriate short-term storage conditions

Appropriate long-term storage conditions

Aliquoting information

Storage information

Supplementary information

Biological function summary

Pathways

Product protocols

Target data

Publications (48)

Product promise